David Uihwan Lee, Ashton Harmacinski, Aneesh Bahadur, K. Lee, Hannah Chou, Mohammed Rifat Shaik, H. Chou, Gregory H. Fan, Jean Kwon, Reid Ponder, Kevin Chang, K. Lee, Z. Lominadze
{"title":"威尔逊氏病对住院病人费用的影响:对美国医院的分析。","authors":"David Uihwan Lee, Ashton Harmacinski, Aneesh Bahadur, K. Lee, Hannah Chou, Mohammed Rifat Shaik, H. Chou, Gregory H. Fan, Jean Kwon, Reid Ponder, Kevin Chang, K. Lee, Z. Lominadze","doi":"10.1097/MEG.0000000000002777","DOIUrl":null,"url":null,"abstract":"BACKGROUND AND AIM\nIn this study, we used a national cohort of patients with Wilson's disease (WD) to investigate the admissions, mortality rates, and costs over the captured period to assess specific subpopulations at higher burden.\n\n\nMETHODS\nPatients with WD were selected using 2016-2019 National Inpatient Sample (NIS). The weighted estimates and patient data were stratified using demographics and medical characteristics. Regression curves were graphed to derive goodness-of-fit for each trend from which R2 and P values were calculated.\n\n\nRESULTS\nAnnual total admissions per 100 000 hospitalizations due to WD were 1075, 1180, 1140, and 1330 (R2 = 0.75; P = 0.13) from 2016 to 2019. Within the demographics, there was an increase in admissions among patients greater than 65 years of age (R2 = 0.90; P = 0.05) and White patients (R2 = 0.97; P = 0.02). Assessing WD-related mortality rates, there was an increase in the mortality rate among those in the first quartile of income (R2 = 1.00; P < 0.001). The total cost for WD-related hospitalizations was $20.90, $27.23, $24.20, and $27.25 million US dollars for the years 2016, 2017, 2018, and 2019, respectively (R2 = 0.47; P = 0.32). There was an increasing total cost trend for Asian or Pacific Islander patients (R2 = 0.90; P = 0.05). Interestingly, patients with cirrhosis demonstrated a decreased trend in the total costs (R2 = 0.97; P = 0.02).\n\n\nCONCLUSION\nOur study demonstrated that certain ethnicity groups, income classes and comorbidities had increased admissions or costs among patients admitted with WD.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The cost implications of Wilson disease among hospitalized patients: analysis of USA hospitals.\",\"authors\":\"David Uihwan Lee, Ashton Harmacinski, Aneesh Bahadur, K. Lee, Hannah Chou, Mohammed Rifat Shaik, H. Chou, Gregory H. Fan, Jean Kwon, Reid Ponder, Kevin Chang, K. Lee, Z. Lominadze\",\"doi\":\"10.1097/MEG.0000000000002777\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND AND AIM\\nIn this study, we used a national cohort of patients with Wilson's disease (WD) to investigate the admissions, mortality rates, and costs over the captured period to assess specific subpopulations at higher burden.\\n\\n\\nMETHODS\\nPatients with WD were selected using 2016-2019 National Inpatient Sample (NIS). The weighted estimates and patient data were stratified using demographics and medical characteristics. Regression curves were graphed to derive goodness-of-fit for each trend from which R2 and P values were calculated.\\n\\n\\nRESULTS\\nAnnual total admissions per 100 000 hospitalizations due to WD were 1075, 1180, 1140, and 1330 (R2 = 0.75; P = 0.13) from 2016 to 2019. Within the demographics, there was an increase in admissions among patients greater than 65 years of age (R2 = 0.90; P = 0.05) and White patients (R2 = 0.97; P = 0.02). Assessing WD-related mortality rates, there was an increase in the mortality rate among those in the first quartile of income (R2 = 1.00; P < 0.001). The total cost for WD-related hospitalizations was $20.90, $27.23, $24.20, and $27.25 million US dollars for the years 2016, 2017, 2018, and 2019, respectively (R2 = 0.47; P = 0.32). There was an increasing total cost trend for Asian or Pacific Islander patients (R2 = 0.90; P = 0.05). Interestingly, patients with cirrhosis demonstrated a decreased trend in the total costs (R2 = 0.97; P = 0.02).\\n\\n\\nCONCLUSION\\nOur study demonstrated that certain ethnicity groups, income classes and comorbidities had increased admissions or costs among patients admitted with WD.\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MEG.0000000000002777\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MEG.0000000000002777","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
The cost implications of Wilson disease among hospitalized patients: analysis of USA hospitals.
BACKGROUND AND AIM
In this study, we used a national cohort of patients with Wilson's disease (WD) to investigate the admissions, mortality rates, and costs over the captured period to assess specific subpopulations at higher burden.
METHODS
Patients with WD were selected using 2016-2019 National Inpatient Sample (NIS). The weighted estimates and patient data were stratified using demographics and medical characteristics. Regression curves were graphed to derive goodness-of-fit for each trend from which R2 and P values were calculated.
RESULTS
Annual total admissions per 100 000 hospitalizations due to WD were 1075, 1180, 1140, and 1330 (R2 = 0.75; P = 0.13) from 2016 to 2019. Within the demographics, there was an increase in admissions among patients greater than 65 years of age (R2 = 0.90; P = 0.05) and White patients (R2 = 0.97; P = 0.02). Assessing WD-related mortality rates, there was an increase in the mortality rate among those in the first quartile of income (R2 = 1.00; P < 0.001). The total cost for WD-related hospitalizations was $20.90, $27.23, $24.20, and $27.25 million US dollars for the years 2016, 2017, 2018, and 2019, respectively (R2 = 0.47; P = 0.32). There was an increasing total cost trend for Asian or Pacific Islander patients (R2 = 0.90; P = 0.05). Interestingly, patients with cirrhosis demonstrated a decreased trend in the total costs (R2 = 0.97; P = 0.02).
CONCLUSION
Our study demonstrated that certain ethnicity groups, income classes and comorbidities had increased admissions or costs among patients admitted with WD.